Searchable abstracts of presentations at key conferences in endocrinology

ea0056p299 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2018

PCSK9 inhibitors as an add on for the treatment of dislipemia in real clinical practice

Garcia Carmen Hernandez , Perdigones Cristina Maria Diaz , Fuentes Miguel Damas , Martinez Clara Estaun , Ramos Andrea Sanchez , Ramos Ana Molina , Madueno Francisco Tinahones

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...